Analyses of Protease Resistance and Aggregation State of Abnormal Prion Protein Across the Spectrum of Human Prions
Overview
Authors
Affiliations
Prion diseases are characterized by tissue accumulation of a misfolded, β-sheet-enriched isoform (scrapie prion protein (PrP(Sc))) of the cellular prion protein (PrP(C)). At variance with PrP(C), PrP(Sc) shows a partial resistance to protease digestion and forms highly aggregated and detergent-insoluble polymers, two properties that have been consistently used to distinguish the two proteins. In recent years, however, the idea that PrP(Sc) itself comprises heterogeneous species has grown. Most importantly, a putative proteinase K (PK)-sensitive form of PrP(Sc) (sPrP(Sc)) is being increasingly investigated for its possible role in prion infectivity, neurotoxicity, and strain variability. The study of sPrP(Sc), however, remains technically challenging because of the need of separating it from PrP(C) without using proteases. In this study, we have systematically analyzed both PK resistance and the aggregation state of purified PrP(Sc) across the whole spectrum of the currently characterized human prion strains. The results show that PrP(Sc) isolates manifest significant strain-specific differences in their PK digestion profile that are only partially explained by differences in the size of aggregates, suggesting that other factors, likely acting on PrP(Sc) aggregate stability, determine its resistance to proteolysis. Fully protease-sensitive low molecular weight aggregates were detected in all isolates but in a limited proportion of the overall PrP(Sc) (i.e. <10%), arguing against a significant role of slowly sedimenting PK-sensitive PrP(Sc) in the biogenesis of prion strains. Finally, we highlight the limitations of current operational definitions of sPrP(Sc) and of the quantitative analytical measurements that are not based on the isolation of a fully PK-sensitive PrP(Sc) form.
Proteomic Evidence for Amyloidogenic Cross-Seeding in Fibrinaloid Microclots.
Kell D, Pretorius E Int J Mol Sci. 2024; 25(19).
PMID: 39409138 PMC: 11476703. DOI: 10.3390/ijms251910809.
Venom-derived peptides for breaking through the glass ceiling of drug development.
Freuville L, Matthys C, Quinton L, Gillet J Front Chem. 2024; 12:1465459.
PMID: 39398192 PMC: 11468230. DOI: 10.3389/fchem.2024.1465459.
A Comparison of RML Prion Inactivation Efficiency by Heterogeneous and Homogeneous Photocatalysis.
Paspaltsis I, Kanata E, Sotiriadis S, Correia S, Schmitz M, Zerr I Pathogens. 2024; 13(5).
PMID: 38787272 PMC: 11124347. DOI: 10.3390/pathogens13050420.
Extensive accumulation of misfolded protein aggregates during natural aging and senescence.
Cuanalo-Contreras K, Schulz J, Mukherjee A, Park K, Armijo E, Soto C Front Aging Neurosci. 2023; 14:1090109.
PMID: 36778589 PMC: 9909609. DOI: 10.3389/fnagi.2022.1090109.
The Use of Real-Time Quaking-Induced Conversion for the Diagnosis of Human Prion Diseases.
Poleggi A, Baiardi S, Ladogana A, Parchi P Front Aging Neurosci. 2022; 14:874734.
PMID: 35547619 PMC: 9083464. DOI: 10.3389/fnagi.2022.874734.